Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
株式のランク #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
株価
$0.0001
最終同期: 2023-05-22
時価総額
$10.03K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 NuGenerex Immuno-Oncology, Inc. (NUGX)

カテゴリー

NuGenerex Immuno-Oncology, Inc.(NUGX)のEPS
2026 時点のEPS TTM: 0
NuGenerex Immuno-Oncology, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
NuGenerex Immuno-Oncology, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS